+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 1Month - 18Years
All Genders
ID01949129

Optimizing Conditioning Regimens in Pediatric and Adolescent Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplantation

Led by St. Anna Kinderkrebsforschung · Updated on 2026-09-04

1800

Participants Needed

119

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are conducting a multinational phase III study to optimize therapy for children and adolescents with acute lymphoblastic leukemia ALL in complete remission who require allogeneic hematopoietic stem cell transplantation HSCT with a myeloablative conditioning regimen. The study aims to compare chemotherapy-based conditioning regimens with total body irradiation TBI combined with etoposide, focusing on treatment outcomes and side effects. This research addresses the need for safer conditioning options due to the significant long-term toxicities associated with TBI in growing patients. Participants receive different conditioning regimens before HSCT based on age, donor type, and country-specific protocols. The main options include TBI with etoposide for patients older than 4 years, and chemotherapy combinations such as fludarabine, thiotepa, treosulfan, busulfan, and cyclophosphamide for younger patients or those ineligible for TBI. Various donor types, including matched sibling donors, matched unrelated donors, and mismatched donors, are included, with additional treatments like ATG or T-cell depletion depending on donor matching. Throughout the study, participants undergo regular evaluations including survival monitoring and adverse event tracking for up to 10 years. Assessments focus on overall survival, event-free survival, relapse, and treatment-related toxicity. Data collection includes long-term follow-up to investigate factors affecting outcomes such as immune recovery, graft-versus-host disease, and pharmacogenomics. The total study duration can extend to several years to thoroughly assess late effects and survival rates.

CONDITIONS

Brief Title

Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

Research Team

C

Christina Peters, Prof. MD PhD

T

Tijana Frank, MD, MScEng

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here